The company, which also said it is short on funds, may have to pay $18.3 million to Hudson Bay Master Fund if forebearance is not granted for the default.
Investigators will use Biocept's liquid biopsy tests to detect ALK rearrangements both at baseline and to monitor treatment response and resistance mechanisms.
The study, launched today, aims to evaluate the use of liquid biopsy and natural killer cell testing for the early detection of recurrent breast cancer.
The offering consists of two tranches of $600 million each, and the firm plans to use the net proceeds for general corporate purposes, including the repayment of outstanding senior notes due on Aug. 23.
As part of the contract, Abbott will supply analytical equipment and consumables, including the Alinity ci and Alinity h series diagnostics instruments.
The firm missed analysts' expectations on both the top and bottom lines, despite a reported 20 percent increase in clinical services revenues during the quarter.
The diagnostic firm plans to sell the shares to BTIG. It also has granted the investment bank the option to purchase up to an additional 375,000 shares.
The company may use the proceeds of the loans to help fund the $7.2 billion acquisition of Patheon. The loan facility follows a $1.5 billion senior notes offering by Thermo Fisher last week.
The scientists argued that studies indicate the creatine kinase-myocardial band testing has no "incremental value to patient care" and outlined steps to put the test to rest.
Roche's HbA1c test, along with an immunoassay system from Shenzhen New Industries Biomedical, and a celiac test from Immco also received 510(k) clearance last month.
The PCR-based test can simultaneously detect for the Zika virus, all serotypes of the dengue virus, the chikungunya virus, the West Nile virus, and a host gene.
The tender offer, which is being extended to allow additional time for the consummation of Abbott's acquisition of Alere, could expire at the end of August.
